Roquefort Therapeutics (LSE:ROQ) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Roquefort Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Roquefort Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Roquefort Therapeutics's Cash-to-Debt or its related term are showing as below:

LSE:ROQ' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 3 years, Roquefort Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

LSE:ROQ's Cash-to-Debt is ranked better than
99.8% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs LSE:ROQ: No Debt

Roquefort Therapeutics Cash-to-Debt Historical Data

The historical data trend for Roquefort Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Roquefort Therapeutics Cash-to-Debt Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Roquefort Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Roquefort Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roquefort Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Cash-to-Debt falls into.

Roquefort Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Roquefort Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Roquefort Therapeutics had no debt ⁽¹⁾.

Roquefort Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Roquefort Therapeutics had no debt ⁽¹⁾.

Roquefort Therapeutics (LSE:ROQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Roquefort Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines

Roquefort Therapeutics (LSE:ROQ) Cash-to-Debt : No Debt (1) (As of Dec. 2023)